News

NEWS

SOTIO is building its own laboratories in Beijing

SOTIO representatives signed a contract for the lease of office and laboratory space at the “Huilongsen International Business Incubator (Beijing) Co., Ltd.” biotechnology park in Beijing, China this September. The park is located in the southern part of Beijing known as Yizhuang – one of the Chinese capital’s centers of residential and economic development.

NEWS

SOTIO GMP Manufacturing Process to be Implemented at PCT

ALLENDALE, N.J. and WILMINGTON, Del., July 16, 2012 -- (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. ("SOTIO"), announced today that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC is an affiliate of a Czech Republic-based biotechnology company developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies